Yubo International Biotech (Yubo International Biotech) Change In Receivables : $-0.04 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Yubo International Biotech Change In Receivables?

Yubo International Biotech's change in receivables for the quarter that ended in Mar. 2024 was $-0.03 Mil. It means Yubo International Biotech's Accounts Receivable increased by $0.03 Mil from Dec. 2023 to Mar. 2024 .

Yubo International Biotech's change in receivables for the fiscal year that ended in Dec. 2023 was $-0.02 Mil. It means Yubo International Biotech's Accounts Receivable increased by $0.02 Mil from Dec. 2022 to Dec. 2023 .

Yubo International Biotech's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.12 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Yubo International Biotech's Days Sales Outstanding for the three months ended in Mar. 2024 was 3,497.92.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Yubo International Biotech's liquidation value for the three months ended in Mar. 2024 was $-3.36 Mil.

Yubo International Biotech Change In Receivables Historical Data

The historical data trend for Yubo International Biotech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yubo International Biotech Change In Receivables Chart

Yubo International Biotech Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-0.03

-0.13

0.21

-0.02

Yubo International Biotech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial												-0.01	0.02	-	-0.04	-0.03

Yubo International Biotech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.

Yubo International Biotech (OTCPK:YBGJ) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Yubo International Biotech's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.115	/	0.003	*	91
=	3,497.92

2. In Ben Graham's calculation of liquidation value, Yubo International Biotech's accounts receivable are only considered to be worth 75% of book value:

Yubo International Biotech's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.057	-	3.61	+	0.75 * 0.115	+	0.5 * 0.212
=	-3.36

Yubo International Biotech Change In Receivables Related Terms

Thank you for viewing the detailed overview of Yubo International Biotech's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Yubo International Biotech (Yubo International Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Yubo International Biotech Ltd (OTCPK:YBGJ) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

31 Xishiku Avenue, Room 105, Building 5, Xicheng District, Beijing, CHN, 100034

Website

http://www.yubogroup.com

Yubo International Biotech Ltd is a technology company focused on the research and development and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of nebulizers containing frozen tubes with medical fluid and from the sale of oral liquids health products. The nebulizers are sold directly to consumers on its online e-commerce platform.

Executives

Lina Liu	10 percent owner, officer: CFO, Treasurer and Secretary	MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Focus Draw Group Ltd	10 percent owner	C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Boao Biotech Ltd	10 percent owner	C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Flydragon International Ltd	10 percent owner	C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Chinaone Technology Ltd	10 percent owner	C/O YUBO INTERNATIONAL BIOTECH LIMITED, ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Bai Zhihui	director	MAGNU-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Jun	director, officer: President and CEO	MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Wang Yang	director	MAGNA-LAB, INC., ROOM 105, BUILDING 5, 31 XISHIKU AVENUE, XICHENG DISTRICT, BEIJING F4 00000
Joel S Kanter	director	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Jonathan Adereth	director	C/O MEDIVISION, PO BOX 45 INDUSTRIAL PARK, YOKNEAM ISRAEL
Magna Acquisition Llc	10 percent owner	8000 TOWERS CRESCENT DRIVE, SUITE 1070, VIENNA VA 22182
Kenneth C Riscica	officer: Treasurer and Secretary	C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Lawrence A Minkoff	director, officer: Chairman, President, CSO	C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE, SUITE 120W, SYOSSET NY 11791
Jerome M Feldman	director	C/O MAGNA-LAB INC, 6800 JERICHO TURNPIKE SUITE 120W, SYOSSET NY 11791
Seymour Kessler	director	C/O MAGNA-LAB INC., 6800 JERICHO TURNPIKE #120W, SYOSSET NY 11791

Yubo International Biotech (Yubo International Biotech) Headlines

No Headlines